返回 
加入收藏
芦可替尼治疗骨髓纤维化的疗效与安全性
x
请在关注微信后，向客服人员索取文件
| 篇名： | 芦可替尼治疗骨髓纤维化的疗效与安全性 |
| TITLE： | Efficacy and safety of ruxolitinib in the treatment of myelofibrosis |
| 摘要： | 目的 探究芦可替尼治疗骨髓纤维化（MF）的疗效和安全性。方法回顾性收集2018年9月至2024年4月于蚌埠市第三人民医院就诊且规范使用芦可替尼超过6个月的42例MF患者资料。分析治疗前后患者的临床症状评分、脾脏缩小情况和MF分级情况，并记录关联性评价结果为“肯定“”很可能“”可能有关”的不良反应的发生情况，随访患者的生存情况。结果治疗6个月后，患者的各单项临床症状评分及总分均较治疗前显著降低（P＜0.05），脾脏长径、厚径均较治疗前显著缩短（P＜0.05）。5例患者的MF分级较基线下降1级，1例由MF-2级下降至MF-0级，14例MF分级未发生变化。不良反应以贫血（26例次）、血小板减少（14例次）、感染（11例次）、胃肠道不适（9例次）为主。39例患者存活，生存率为92.86%。结论芦可替尼能有效改善MF患者的临床症状，缩小脾脏，稳定甚至改善MF分级，有望为MF患者带来长期生存获益；不良反应主要表现为贫血、血小板减少、感染及胃肠道不适。 |
| ABSTRACT： | OBJECTIVE To explore the efficacy and safety of ruxolitinib in the treatment of myelofibrosis （MF）. METHODS A retrospective collection of data was conducted on 42 MF patients who were treated with ruxolitinib in a standardized manner for more than 6 months in the Third People’s Hospital of Bengbu from September 2018 to April 2024. The clinical symptom scores， spleen size reduction， and MF grading of the patients before and after treatment were analyzed. Additionally， the occurrence of adverse reactions with a causality assessment result of “definite”“probable” or “possible” was recorded. The patients’ survival status was followed up. RESULTS After 6 months of treatment， both clinical symptom scores and the total score were significantly decreased than before treatment （P＜0.05）. The length and thickness of the spleen were significantly shorter than before treatment （P＜0.05）. MF classification in 5 patients decreased by 1 level compared with baseline， 1 case was level 2 and dropped to level 0， 14 patients remained stable. The main adverse reactions were anemia （26 cases）， thrombocytopenia （14 cases）， infection （11 cases）， and gastrointestinal discomfort （9 cases）. Thirty-nine patients survived， with a survival rate of 92.86%. CONCLUSIONS Ruxolitinib can effectively improve the clinical symptoms of patients with MF， shrink the spleen， stabilize and even improve MF grading， and holds promise for bringing long-term survival benefits to MF patients. Adverse reactions are mainly anemia， thrombocytopenia， infection and gastrointestinal discomfort. |
| 期刊： | 2025年第36卷第14期 |
| 作者： | 王菀菀；叶隽；程海；姚伟；刘桂玲 |
| AUTHORS： | WANG Wanwan，YE Jun，CHENG Hai，YAO Wei，LIU Guiling |
| 关键字： | 芦可替尼；骨髓纤维化；疗效；安全性 |
| KEYWORDS： | ruxolitinib； myelofibrosis； efficacy； safety |
| 阅读数： | 10 次 |
| 本月下载数： | 0 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
